Yahoo Finance • 13 days ago
Investors in Tarsus Pharmaceuticals Inc (Symbol: TARS) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TARS options chain for the new... Full story
Yahoo Finance • last month
IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20th Annual Healthcare Confe... Full story
Yahoo Finance • 2 months ago
Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q2 2025 MANAGEMENT VIEW * CEO Bobak R. Azamian highlighted that "we delivered record-breaking results of more than $100 million in net sales and approximately 91,000 bottles dispens... Full story
Yahoo Finance • 2 months ago
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and le... Full story
Yahoo Finance • 2 months ago
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 202... Full story
Yahoo Finance • 5 months ago
We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) stands against other best breakout stocks to buy accordi... Full story
Yahoo Finance • 5 months ago
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the i... Full story
Yahoo Finance • 7 months ago
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at... Full story
Yahoo Finance • 7 months ago
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stoc... Full story
Yahoo Finance • 7 months ago
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, Marc... Full story
Yahoo Finance • 7 months ago
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter an... Full story
Yahoo Finance • 2 years ago
In this article, we will take a detailed look at the11 Stocks That Will Make You Rich in 5-10 Years. For a quick overview of such stocks, read our article 5Stocks That Will Make You Rich in 5-10 Years. Can investing in stocks make you ric... Full story
Yahoo Finance • 2 years ago
Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 mill... Full story
Yahoo Finance • 2 years ago
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story
Yahoo Finance • 2 years ago
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with e... Full story
Yahoo Finance • 2 years ago
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story
Yahoo Finance • 2 years ago
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provi... Full story
Yahoo Finance • 2 years ago
IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story
Yahoo Finance • 2 years ago
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye... Full story